In the phase 2 MIRO-CKD trial, 12 weeks of balcinrenone combined with dapagliflozin reduced albuminuria compared with dapagliflozin alone added to standard of care in patients with stage 3-4 CKD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results